Daniel P. Petrylak, MD, presented “Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma” for the Grand Rounds in Urology audience in January, 2020.
How to cite: Petrylak, Daniel P. “Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma” January, 2020. Accessed Nov 2024. https://grandroundsinurology.com/enfortumab-vedotin-approved-by-fda-for-patients-with-refractory-urothelial-carcinoma/
Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma – Summary:
Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and of Urology, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, discusses the recent FDA approval of the antibody drug complex enfortumab vedotin for treating refractory advanced urothelial disease in patients previously treated with immunotherapy and chemotherapy. He describes how the drug complex works to fight bladder cancer by recognizing Nectin-4, a biomarker expressed on the surface of bladder cancer cells, and delivering MMAE to cause cytotoxic activity. Dr. Petrylak further describes the design, execution, and results of the clinical trial that led to the drug’s approval, as well as notable side effects.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
